Senís Elena, Fatouros Chronis, Große Stefanie, Wiedtke Ellen, Niopek Dominik, Mueller Ann-Kristin, Börner Kathleen, Grimm Dirk
Heidelberg University Hospital, Cluster of Excellence CellNetworks, Centre for Infectious Diseases, Virology, Heidelberg, Germany.
Biotechnol J. 2014 Nov;9(11):1402-12. doi: 10.1002/biot.201400046. Epub 2014 Oct 6.
Its remarkable ease and efficiency make the CRISPR (clustered regularly interspaced short palindromic repeats) DNA editing machinery highly attractive as a new tool for experimental gene annotation and therapeutic genome engineering in eukaryotes. Here, we report a versatile set of plasmids and vectors derived from adeno-associated virus (AAV) that allow robust and specific delivery of the two essential CRISPR components - Cas9 and chimeric g(uide)RNA - either alone or in combination. All our constructs share a modular design that enables simple and stringent guide RNA (gRNA) cloning as well as rapid exchange of promoters driving Cas9 or gRNA. Packaging into potent synthetic AAV capsids permits CRISPR delivery even into hard-to-transfect targets, as shown for human T-cells. Moreover, we demonstrate the feasibility to direct Cas9 expression to or away from hepatocytes, using a liver-specific promoter or a hepatic miRNA binding site, respectively. We also report a streamlined and economical protocol for detection of CRISPR-induced mutations in less than 3 h. Finally, we provide original evidence that AAV/CRISPR vectors can be exploited for gene engineering in vivo, as exemplified in the liver of adult mice. Our new tools and protocols should foster the broad application of CRISPR technology in eukaryotic cells and organisms, and accelerate its clinical translation into humans.
CRISPR(规律成簇的间隔短回文重复序列)DNA编辑机制因其显著的简便性和高效性,作为一种用于真核生物实验性基因注释和治疗性基因组工程的新工具极具吸引力。在此,我们报道了一组源自腺相关病毒(AAV)的多功能质粒和载体,它们能够单独或联合高效且特异性地递送CRISPR的两个关键组分——Cas9和嵌合向导RNA(gRNA)。我们所有的构建体都采用模块化设计,能够实现简单且严格的向导RNA(gRNA)克隆,以及驱动Cas9或gRNA的启动子的快速交换。包装到高效的合成AAV衣壳中,即使对于难以转染的靶标(如人类T细胞)也能实现CRISPR递送。此外,我们分别利用肝脏特异性启动子或肝脏微小RNA结合位点,证明了将Cas9表达导向肝细胞或使其远离肝细胞的可行性。我们还报道了一种简化且经济的方案,可在不到3小时内检测CRISPR诱导的突变。最后,我们提供了原始证据,证明AAV/CRISPR载体可用于体内基因工程,如在成年小鼠肝脏中的实例所示。我们的新工具和方案应能促进CRISPR技术在真核细胞和生物体中的广泛应用,并加速其向人类临床应用的转化。